Saturday 17 October 2026 Export VMD’s income statement to Excel — free account

Viemed Healthcare, Inc.

Viemed Healthcare, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $270.3 million, up 20.5% from fiscal 2024. In the quarter to June 2026, revenue grew 23.9%, EPS fell 12.5%, free cash flow fell 18.2% and total debt rose 65.5%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

9.48 0.27 −2.77%

Follow VMD

Alert me

Market cap: $371.4M
P/E: 24.9×
Fwd P/E: 21.9×
Dividend yield: —
F-score: 5/9
Altman Z: 5.58
Beneish M: −3.18
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.59

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	1	—	—	2	—	—	—	—

Insider Ownership 14.29%

Capital & Financial Ratios $m

Market Cap 371.36

Revenue 301.61

Net Income 15.03

Free Cash Flow 34.43

Net Debt (3.59)

Current Ratio 1.13

Debt/Equity 0.05

P/E ratio 24.95

Fwd P/E 21.90

P/S ratio 1.20

P/B ratio 2.48

Past 5Y EPS Growth (13.86%)

This Y EPS Growth 11.71%

Next Y EPS Growth 31.45%

Next Y revenue growth 17.62%

Next 5Y EPS Growth 23.09%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 40.33%

10-year low 10-year high

P/S against its own 10 years 13.55%

10-year low 10-year high

P/B against its own 10 years 32.97%

10-year low 10-year high

EV/Sales against its own 10 years 15.05%

10-year low 10-year high

EV/FCF against its own 10 years 9.85%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	13	18	14	11
Receivables	18	25	26	32
Inventory	5	4	5	5
Other	—	—	—	—
	38	53	48	54

	2023	2024	2025	Q'26
Payables	4	5	7	11
ST’ Debt	1	0	1	1
Other	—	—	—	—
	32	37	41	48

Compound Annual Growth %

	10y	5y	3y
Sales	—	15.53%	24.87%
Cash Flow	—	8.14%	23.22%
Earnings	—	(13.88%)	33.89%
Book Value	—	11.93%	13.91%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	75	78	—	—	—
’25	59	63	72	76	270
’24	51	55	58	61	224
’23	40	43	49	51	183
’22	32	33	36	38	139
’21	28	27	29	32	117
’20	24	43	33	31	131

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	8	16	—	—	—
’25	3	12	18	18	52
’24	1	10	13	15	39
’23	10	8	14	13	45
’22	7	5	8	8	28
’21	5	4	5	9	22
’20	1	21	7	6	35

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	3	9	—	—	—
’25	(6)	11	12	11	28
’24	(4)	2	8	6	12
’23	7	3	7	6	22
’22	3	(2)	2	2	6
’21	3	1	(3)	2	3
’20	(1)	22	5	1	27

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.06	0.07	—	—	—
’25	0.06	0.08	0.09	0.14	0.37
’24	0.04	0.04	0.10	0.10	0.28
’23	0.04	0.06	0.07	0.09	0.25
’22	0.04	0.02	0.03	0.06	0.16
’21	0.04	0.04	0.04	0.10	0.22
’20	0.11	0.48	0.07	0.12	0.78

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	5.90	2.44	4.96	3.56	5.90	6.21	5.93	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	8.73	11.98	10.96	8.06	12.01	10.44	8.62
People
People	Employees	—	—	321	418	511	627	743	996	1,179	1,382
	Revenue/emp, $m	0.00	0.00	0.20	0.19	0.26	0.19	0.19	0.18	0.19	0.20
Income, $m
Income, $m	Revenue	31	47	64	80	131	117	139	183	224	270
	Gross margin, %	75.28	73.76	74.11	69.78	61.01	62.71	60.99	61.63	59.40	57.52
	EBT	0	8	10	9	26	13	9	14	16	22
	EBT margin, %	0.35	17.45	15.00	10.96	20.08	10.68	6.48	7.86	7.21	8.05
	Net income	1	8	10	9	32	9	6	10	11	15
	Depreciation	1	3	4	6	10	11	16	22	26	29
Per share, $
Per share, $	Revenue	0.81	1.24	1.70	2.13	3.39	2.96	3.59	4.77	5.79	6.95
	Earnings	0.03	0.22	0.27	0.23	0.81	0.23	0.16	0.27	0.29	0.38
	Cash flow	0.17	0.32	0.59	0.51	0.91	0.57	0.72	1.18	1.01	1.33
	Capex	0.00	(0.09)	(0.14)	(0.34)	(0.20)	(0.48)	(0.56)	(0.61)	(0.71)	(0.61)
	Free cash flow	0.17	0.22	0.45	0.17	0.71	0.08	0.15	0.57	0.30	0.72
	Book value	0.34	0.63	0.86	1.16	2.11	2.40	2.51	2.97	3.44	3.69
	Shares, m	38	38	38	38	39	39	39	38	39	39
Valuation, ×
Valuation, ×	P/E	1,104,377.10	8.05	267,500.00	26.36	9.58	22.70	50.33	29.59	27.66	19.05
	P/S	0.00	0.00	12,483.42	2.91	2.29	1.76	2.10	1.67	1.39	1.07
	P/B	0.00	0.00	25,016.27	5.35	3.68	2.17	3.01	2.69	2.33	2.01
	EV/Sales	3.55	3.55	3.55	2.90	2.12	1.57	1.99	1.64	1.33	1.07
	EV/FCF	31.59	31.59	31.59	37.11	10.18	54.91	46.61	13.86	25.54	10.25
Cash, $m
Cash, $m	Operating cash flow	6	12	22	19	35	22	28	45	39	52
	Capex	(2)	(4)	(5)	(13)	(8)	(19)	(22)	(24)	(27)	(24)
	Free cash flow	6	8	17	6	27	3	6	22	12	28
Balance, $m
Balance, $m	Working capital	2	4	4	2	24	29	21	6	16	7
	Total debt	6	5	3	12	8	6	1	7	4	12
	Net debt	2	0	(7)	(1)	(23)	(22)	(16)	(6)	(14)	(1)
	Shareholders’ equity	13	24	33	44	82	95	97	114	133	144
Returns, %
Returns, %	ROA	3.87	26.29	20.82	12.51	32.31	7.92	5.30	7.53	6.79	7.94
	ROIC	0.00	23.14	24.86	13.48	21.68	8.97	5.88	8.59	8.44	8.98
	ROE	6.59	44.75	33.77	22.35	50.29	10.34	6.48	9.71	9.11	10.79

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CERS Cerus Corporation	$455.5M	— (loss-making)	— (loss-making)	+5.28% (above 0%: growing)	n/m	−20.90% (below 0%: shrinking)	55.91%	(2.94%)	Compare
NPCE NeuroPace, Inc.	$438.7M	— (loss-making)	— (loss-making)	+17.05% (above 0%: growing)	n/m	−78.70% (below 0%: shrinking)	82.83%	(22.53%)	Compare
SENS Senseonics Holdings, Inc.	$435.2M	— (loss-making)	— (loss-making)	+117.82% (above 0%: growing)	n/m	−223.24% (below 0%: shrinking)	59.10%	(248.48%)	Compare
OFIX ORTHOFIX MEDICAL INC.	$390.6M	— (loss-making)	— (loss-making)	+3.85% (above 0%: growing)	n/m	−516.58% (below 0%: shrinking)	70.97%	(3.86%)	Compare
SI Shoulder Innovations, Inc.	$382.4M	— (loss-making)	— (loss-making)	+55.95% (above 0%: growing)	n/m	−52.42% (below 0%: shrinking)	78.26%	(58.43%)	Compare
VMD Viemed Healthcare, Inc.	$371.4M	24.9×	21.9×	+23.85% (above 0%: growing)	−12.50% (below 0%: shrinking)	−18.15% (below 0%: shrinking)	57.68%	6.39%
CV CapsoVision, Inc.	$343.2M	2.1×	— (loss-making)	+9.89% (above 0%: growing)	n/m	−84.44% (below 0%: shrinking)	51.36%	(208.07%)	Compare
RCEL Avita Medical Inc.	$333.1M	— (loss-making)	— (loss-making)	+17.83% (above 0%: growing)	n/m	+66.52% (above 0%: growing)	81.87%	(28.42%)	Compare
CLPT ClearPoint Neuro, Inc.	$294.1M	— (loss-making)	— (loss-making)	+18.07% (above 0%: growing)	n/m	−173.51% (below 0%: shrinking)	61.67%	(94.15%)	Compare
Median of peers	$386.5M	—	—	+17.44%	—	−81.57%	66.32%	(43.42%)

All 149 Medical Devices stocks →

Viemed Healthcare, Inc. (VMD) key facts

Strength: Viemed Healthcare, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $270.3 million, up 20.5% from fiscal 2024.
Viemed Healthcare, Inc. (VMD) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, VMD traded at $9.48, a market capitalization of $371.4 million.
Return on equity was 10.8% and debt-to-equity 0.05.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 5.58 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.